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Introduction
Compounds which increase cGMP levels are implicated in
migraine pathophysiology as well as stroke recovery.
Inhibitors of the cGMP degrading enzyme phosphodieste-
rase type 5 (PDE5) induce headache and migraine in
humans, however surprisingly and unlike other migraine
inducing drugs without measurable dilatation of cerebral
arteries [1] or changes in hemodynamic response or excit-
ability [2]. We aimed to investigate whether sildenafil and
tadalafil induced dilatation of rat middle cerebral and
meningeal arteries in vitro and in vivo.
Methods
Dilatory responses of middle cerebral arteries from
Sprague-Dawley rats were investigated using pressurised
arteriograhy with application of the UK 114–542, sildena-
fil, tadalafil either intraluminally or extraluminally.
Effects of i.v sildenafil and tadalafil on dural arteries in a
closed cranial window in vivo rat model were investi-
gated.
Results
Abluminal sildenafil induced dilatation only at concen-
trations above 0.1 μM with a pEC50 of 6.74 ± 0.86 and
Emax of 36.3 ± 8.3. UK 114542 was slightly more potent
with Emax 70.4 ± 14.4% and pEC50 of 6.8 ± 0.05 (n = 4).
Abluminal application of tadalafil (n = 4) showed no dil-
atory effect compared to control. When applied luminally
all PDE5 inhibitors elicited a slight contraction of approx-
imately 10% at higher doses (n = 4).
Sildenafil dilated dural arteries at high doses in a dose
dependent manner (0.5 to 3 mg/kg), with 1 mg/kg pro-
ducing 60 ± 14% dilatation (n = 6). Tadalafil, however,
failed to elicit significant dilatations in vivo.
Discussion
The selective PDE5 inhibitors tadalafil and sildenafil are
poor vasodilators of intact cerebral arteries. Only at high
concentrations where unspecific effects may prevail did
they induce dilatation. In vivo, the rat dural artery may
dilate at lower doses of the PDE5 inhibitors, than in vitro
however still doses higher than the normal therapeutic
level. In pain generation primary vascular effects of PDE5
inhibitors seems unrelated to migraine generation. Fur-
ther, in intact cerebral arteries PDE5 inhibitor in clinical
doses appear to mixed vascular effects at high doses.
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